CD274 and non-small cell lung carcinoma: Specifically, the PACIFIC trial (PD-L1 inhibitor, Durvalumab vs. placebo for stage III NSCLC) reported a BrMs rate of 11.8% in the placebo arm and 6.3% in the treatment arm at a median follow-up period of 25.2 months (7).